Top Tweets for #CheckMate459

8 days ago

🔥 New #biomarker insights for advanced #HCC from the #CheckMate459 phase III trial! @JHEP_Reports Key findings on first-line #Nivolumab vs. #Sorafenib efficacy: 👉 High T-cell inflammation & high tumor PD-L1 (CPS ≥10) = Improved survival with Nivolumab. 👉 Circulating markers: High IFNγ, low pro-collagen 11, and low granulocytic MDSCs are linked to better Nivolumab outcomes. 👉 Unaltered Wnt/β-catenin pathway favored Nivolumab, while a mutated pathway improved survival with Sorafenib. 🤔 Need to validate in today's IO-based combos! DOI: https://t.co/bAyXstK6P4 #LiverX @ILCAnews @EASLnews @myESMO

hongjaechon's tweet photo. 🔥 New #biomarker insights for advanced #HCC from the #CheckMate459 phase III trial! @JHEP_Reports
Key findings on first-line #Nivolumab vs. #Sorafenib efficacy:
👉 High T-cell inflammation & high tumor PD-L1 (CPS ≥10) = Improved survival with Nivolumab.
👉 Circulating markers: High IFNγ, low pro-collagen 11, and low granulocytic MDSCs are linked to better Nivolumab outcomes.
👉 Unaltered Wnt/β-catenin pathway favored Nivolumab, while a mutated pathway improved survival with Sorafenib.
🤔 Need to validate in today's IO-based combos!
DOI: https://t.co/bAyXstK6P4
#LiverX @ILCAnews @EASLnews @myESMO

vitzie @vitzie

about 7 years ago

Nivolumab for 1L HCC #checkmate459. 全体的には良好ながら、残念ながらnegative study. 単剤では厳しかった。

Top Tweets for #CheckMate459

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users